Blog

GI View

GI View Receives 510(K) FDA Clearance for the Aer-O-Scope™ Colonoscope System for Colorectal Cancer Screening. Aer-O-Scope™ is the only single use, self propelled colonoscope with full 360° Omni-directional View of the colon
Ramat Gan, Israel, December 2, 2014, GI View, developer of advanced GI screening systems, announced today that it has received FDA 510(k) clearance for

Gamida Cell Ltd.

Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company
Jerusalem, Israel, August 19, 2014 — Gamida Cell, a world leader in stem cell expansion technologies and therapeutic products, announced today that it has signed an investment and option agreement with Novartis Pharma AG (“Novartis”). According to the agreement, Novartis will invest $35 million in

Rewalk Robotics Ltd.

ReWalk Robotics Announces Reimbursement Coverage by Major German Insurance Company
YOKNEAM ILIT, ISRAEL / BERLIN, GERMANY / MARLBOROUGH, MASSACHUSETTS, September 23, 2014–ReWalk Robotics Ltd. (Nasdaq: RWLK) (d.b.a. Argo Medical Technologies in Germany) announced today that a major German insurance company is the first to reimburse a ReWalk system for Personal use. ReWalk Robotics has been working

Rewalk Robotics Ltd.

ReWalk Robotics Ltd. Files Registration Statement for Proposed Initial Public Offering
YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., July 10, 2014 — ReWalk Robotics Ltd. (“ReWalk”) today announced that it has filed a registration statement on Form F-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its ordinary shares. The

Rewalk Robotics Ltd.

ReWalk™ Personal Exoskeleton System Cleared by FDA for Home Use Revolutionary technology that allows individuals with Spinal Cord Injury, such as paraplegia, to stand & walk receives clearance for personal use in the U.S.
Marlborough, MA—June 26, 2014 — Exoskeleton leader ReWalk Robotics announced today that the U.S. Food and Drug Administration has cleared the company’s

Orsense Ltd.

OrSense Receives FDA Clearance for its Noninvasive Hemoglobin Monitor
etach Tikva, Israel, November 5, 2013 – OrSense Ltd., developer of solutions for non-invasive measurements of various blood parameters, today announced that it has received FDA clearance for its NBM-200MP, noninvasive hemoglobin (Hb) and pulse oximetry monitor. NBM-200MP belongs to OrSense’s NBM-200 family of products, for the

Orsense Ltd.

OrSense Non Invasive Hemoglobin Monitor Received CFDA Approval for Marketing in China
Petach Tikva, Israel, October 28, 2013 – OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, today announced that it has received China Food and Drug Administration approval for NBM-200, its non-invasive hemoglobin (Hb) system for anemia monitoring and hemorrhage detection.

Gamida Cell Ltd.

 Gamida Cell Announces the Successful Transplantation of the First Patient in The Company’s Phase I/II Study of NiCord® in a Single Cord Configuration
We are witnessing a paradigm shift in transplantation. The first patient was successfully transplanted with a stem cell graft entirely expanded in ex vivo cultures and without the support of a second unit

Orsense Ltd.

OrSense Non Invasive Hemoglobin Monitor Shown Safe and Accurate for Pre-Donation Screening in Blood Banks
OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, announced today that its non-invasive Hemoglobin (Hb) NBM-200 monitor was the topic of multiple recent studies highlighting the clinical value of the device. Four studies, from various countries around

NanoPass Technologies Ltd.

NanoPass Technologies Supports a CDC-Sponsored Phase 3 Study of Polio Vaccine in Infants as Part of its Global Health Initiative
NanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal (into-the-skin or ID) vaccine delivery solutions, is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3 trial of polio vaccine